Rom Leidner is an Oncology physician affiliated with Providence Portland Medical Center. OpenAlex indexes 231 publications with 6,289 citations (h-index 34); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4805 NE Glisan St
Suite 6n40
Portland, OR 972132933
Telephone
503-215-5696Provider last certified this registry record 19 Mar 2021.
Clinical trials
- CAN1012 in Pre-Malignant DCIS and LCIS
Sponsor: Providence Health & Services
- GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Sponsor: Providence Health & Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20251 payment
- Astellas Pharma US IncProgram year20251 payment
- AstraZeneca UK LimitedProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
27.6%Opioid Agonist8.8%Oxycodone Hcl100%Part D≥11 patientsPhenothiazine7%Prochlorperazine Maleate100%Part D≥15 patients+ 3 more classes in this area
Metabolism & gastrointestinal
27.1%Corticosteroid10.3%Prednisone100%Part D≥12 patientsSerotonin-3 Receptor Antagonist7.5%Ondansetron Hcl53%Ondansetron Odt47%Part D<11 patients+ 2 more classes in this area
Hormonal (systemic)
20.6%l-Thyroxine20.6%Levothyroxine Sodium100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer
International Journal of Biological Sciences
2024 - FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment
Cancer Immunology Research
2023 - Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies
Clinical Cancer Research
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Walter Urba, MD, PhD
Providence Portland Medical Center
John Heffner, MD
Providence Portland Medical Center
John Godwin, MD
Providence Portland Medical Center
Alison Conlin, MD
Providence Portland Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”